128 related articles for article (PubMed ID: 8669886)
1. N-myc protein expression in human breast carcinoma: prognostic implications.
Mizukami Y; Nonomura A; Takizawa T; Noguchi M; Michigishi T; Nakamura S; Ishizaki T
Anticancer Res; 1995; 15(6B):2899-905. PubMed ID: 8669886
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical study of oncogene product ras p21, c-myc and growth factor EGF in breast carcinomas.
Mizukami Y; Nonomura A; Noguchi M; Taniya T; Koyasaki N; Saito Y; Hashimoto T; Matsubara F; Yanaihara N
Anticancer Res; 1991; 11(4):1485-94. PubMed ID: 1660689
[TBL] [Abstract][Full Text] [Related]
3. Protein expression and molecular analysis of c-myc gene in primary breast carcinomas using immunohistochemistry and differential polymerase chain reaction.
Naidu R; Wahab NA; Yadav M; Kutty MK
Int J Mol Med; 2002 Feb; 9(2):189-96. PubMed ID: 11786932
[TBL] [Abstract][Full Text] [Related]
4. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
Yu H; Levesque MA; Clark GM; Diamandis EP
Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
[TBL] [Abstract][Full Text] [Related]
5. Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis.
Varley JM; Swallow JE; Brammar WJ; Whittaker JL; Walker RA
Oncogene; 1987; 1(4):423-30. PubMed ID: 3330785
[TBL] [Abstract][Full Text] [Related]
6. MYCN protein expression as a predictor of neuroblastoma prognosis.
Chan HS; Gallie BL; DeBoer G; Haddad G; Ikegaki N; Dimitroulakos J; Yeger H; Ling V
Clin Cancer Res; 1997 Oct; 3(10):1699-706. PubMed ID: 9815553
[TBL] [Abstract][Full Text] [Related]
7. Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours.
Veeck J; Bektas N; Hartmann A; Kristiansen G; Heindrichs U; Knüchel R; Dahl E
Breast Cancer Res; 2008; 10(5):R82. PubMed ID: 18826564
[TBL] [Abstract][Full Text] [Related]
8. Expression of c-myc proteins in breast cancer as related to established prognostic factors and survival.
Pietiläinen T; Lipponen P; Aaltomaa S; Eskelinen M; Kosma VM; Syrjänen K
Anticancer Res; 1995; 15(3):959-64. PubMed ID: 7645986
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis.
Guérin M; Barrois M; Terrier MJ; Spielmann M; Riou G
Oncogene Res; 1988; 3(1):21-31. PubMed ID: 2905033
[TBL] [Abstract][Full Text] [Related]
10. Expression of neuronal protein synuclein gamma gene as a novel marker for breast cancer prognosis.
Wu K; Quan Z; Weng Z; Li F; Zhang Y; Yao X; Chen Y; Budman D; Goldberg ID; Shi YE
Breast Cancer Res Treat; 2007 Mar; 101(3):259-67. PubMed ID: 16821081
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of c-myc proto-oncogene in primary human breast carcinomas.
Pavelic ZP; Steele P; Preisler HD
Anticancer Res; 1991; 11(4):1421-7. PubMed ID: 1660688
[TBL] [Abstract][Full Text] [Related]
12. Activation of myc gene family in human lung carcinomas and during heterotransplantation into nude mice.
Gazzeri S; Brambilla E; Jacrot M; Chauvin C; Benabid AL; Brambilla C
Cancer Res; 1991 May; 51(10):2566-71. PubMed ID: 1850659
[TBL] [Abstract][Full Text] [Related]
13. Expression of transferrin receptor and ferritin H-chain mRNA are associated with clinical and histopathological prognostic indicators in breast cancer.
Yang DC; Wang F; Elliott RL; Head JF
Anticancer Res; 2001; 21(1B):541-9. PubMed ID: 11299801
[TBL] [Abstract][Full Text] [Related]
14. Increase of GKLF messenger RNA and protein expression during progression of breast cancer.
Foster KW; Frost AR; McKie-Bell P; Lin CY; Engler JA; Grizzle WE; Ruppert JM
Cancer Res; 2000 Nov; 60(22):6488-95. PubMed ID: 11103818
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of BRCA2 gene in sporadic breast tumours.
Bièche I; Noguès C; Lidereau R
Oncogene; 1999 Sep; 18(37):5232-8. PubMed ID: 10498873
[TBL] [Abstract][Full Text] [Related]
16. Caspase 3 in breast cancer.
O'Donovan N; Crown J; Stunell H; Hill AD; McDermott E; O'Higgins N; Duffy MJ
Clin Cancer Res; 2003 Feb; 9(2):738-42. PubMed ID: 12576443
[TBL] [Abstract][Full Text] [Related]
17. Expression of c-kit proto-oncogene product in breast tissue.
Yared MA; Middleton LP; Meric F; Cristofanilli M; Sahin AA
Breast J; 2004; 10(4):323-7. PubMed ID: 15239791
[TBL] [Abstract][Full Text] [Related]
18. Expression of the mismatch repair protein hMSH2 in carcinoma in situ and invasive cancer of the breast.
Bock N; Meden H; Regenbrecht M; Jünemann B; Wangerin J; Marx D
Anticancer Res; 2000; 20(1A):119-24. PubMed ID: 10769643
[TBL] [Abstract][Full Text] [Related]
19. Analysis of genetic and epigenetic processes that influence p14ARF expression in breast cancer.
Silva J; Domínguez G; Silva JM; García JM; Gallego I; Corbacho C; Provencio M; España P; Bonilla F
Oncogene; 2001 Jul; 20(33):4586-90. PubMed ID: 11494155
[TBL] [Abstract][Full Text] [Related]
20. Association of C-MYC amplification with progression from the in situ to the invasive stage in C-MYC-amplified breast carcinomas.
Robanus-Maandag EC; Bosch CA; Kristel PM; Hart AA; Faneyte IF; Nederlof PM; Peterse JL; van de Vijver MJ
J Pathol; 2003 Sep; 201(1):75-82. PubMed ID: 12950019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
